Trial · NCT00326183
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Participants With 1 or More Serious Vaccine-Related Adverse Experiences | Days 1 to 14 after any vaccination | Includes all subjects who provided safety follow-up data after any dose of vaccine out of the total number of subjects enrolled. | participants | NUMBER |
| SECONDARY | Participants With 1 or More Systemic Adverse Experiences | Days 1 to 14 After Any Vaccination | Includes all subjects who provided safety follow-up data after any dose of vaccine out of the total number of subjects enrolled. | participants | NUMBER |
| PRIMARY | Participants With 1 or More Injection-Site Adverse Experiences | Days 1 to 14 after any vaccination | Includes all subjects who provided safety follow-up data after any dose of vaccine out of the total number of subjects enrolled. | participants | NUMBER |
| PRIMARY | Participants With Measles-Like Rash After First Vaccination | Days 1 to 28 After First Vaccination | Includes all subjects who provided safety follow-up data after the first vaccinations were administered. Only the VAQTA™ +ProQuad™ group was followed for rashes. | participants | NUMBER |
| PRIMARY | Participants With Measles-Like Rash After Second Vaccination | Days 1 to 28 After Second Vaccination | Includes all subjects who provided safety follow-up data after the second vaccinations were administered. Only the VAQTA™ + ProQuad™ group was followed for rashes. | participants | NUMBER |
| PRIMARY | Participants With Mumps-Like Symptoms After First Vaccination | Days 1 to 28 After First Vaccination | Includes all subjects who provided safety follow-up data after the first vaccinations were administered. Only the VAQTA™ + ProQuad™ group was followed for mumps-like symptoms. | participants | NUMBER |
| PRIMARY | Participants With Mumps-Like Symptoms After Second Vaccination | Days 1 to 28 After Second Vaccination | Includes all subjects who provided safety follow-up data after the second vaccinations were administered. Only the VAQTA™ + ProQuad™ group was followed for mumps-like symptoms. | participants | NUMBER |
| PRIMARY | Participants With Rubella-Like Rash After First Vaccination | Days 1 to 28 After First Vaccination | Includes all subjects who provided safety follow-up data after the first vaccinations were administered. Only the VAQTA™ + ProQuad™ group was followed for rashes. | participants | NUMBER |
| PRIMARY | Participants With Rubella-Like Rash After Second Vaccination | Days 1 to 28 After Second Vaccination | Includes all subjects who provided safety follow-up data after the second vaccinations were administered. Only the VAQTA™ + ProQuad™ group was followed for rashes. | participants | NUMBER |
| PRIMARY | Participants With Varicella/Zoster-Like Rash After First Vaccination | Days 1 to 28 After First Vaccination | Includes all subjects who provided safety follow-up data after the first vaccinations were administered. Only the VAQTA™ + ProQuad™ group was followed for rashes. | participants | NUMBER |
| PRIMARY | Participants With Varicella/Zoster-Like Rash After Second Vaccination | Days 1 to 28 After Second Vaccination | Includes all subjects who provided safety follow-up data after the second vaccinations were administered. Only the VAQTA™ + ProQuad™ group was followed for rashes. | participants | NUMBER |
| PRIMARY | Participants With Elevated Temperature (>=102.2F/39.0C) | Days 1 to 5 After Any Vaccination | Includes all subjects who provided body temperature follow-up data after any dose of vaccine. | participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00326183/outcomes